tirzepatide stock symbol molecule, conceptual illustration - Image - F045/6542 Eli Lilly telehealth partners continue

Metabolic health beyond weight Effects on cardiovascular outcomes, fatty liver, metabolic syndrome

Safety data is limited to the preclinical studies, where no adverse events were reported at therapeutic doses during the 11-week treatment period the longest published study duration

Advise patients to refer to the IFU in case of any change in the presentation

High-fat or high-sugar meals whilst not contraindicated, these may worsen gastrointestinal side effects, particularly during the dose escalation phase

Understanding how tirzepatide affects metabolism and how cagrilintide contributes to weight loss provides a more complete picture of the evolving landscape

ejinme.com/article/S0953- This meta-analysis of 3 placebo-controlled RCTs found that #tirzepatide has a beneficial effect on blood pressure